Biogen completes Nightstar acquisition
The companies announced the acquisition in March this year, with the value estimated at approximately $800 million.
Read More
Tag: Nightstar
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
